Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basking In Phase III Telaprevir Success, Vertex Maps Hepatitis C Market

Executive Summary

After releasing glowing topline Phase III results for telaprevir, Vertex took pains to reassure investors that it is up to the commercial job of competing against Big Pharma and that it has done its homework on the developing hepatitis C market

You may also be interested in...



Vertex Advances Toward Telaprevir Approval

The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.

Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See

Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel